{"nct_id":"NCT04305054","title":"Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-08","start_date":"2020-07-01","start_date_type":"ACTUAL","primary_completion_date":"2026-04-20","primary_completion_date_type":"ESTIMATED","completion_date":"2026-04-20","completion_date_type":"ESTIMATED","phases":["PHASE1","PHASE2"],"tickers":["MRK"]}